Clinical trials: Cognitive Avoidance
Cognitive Impairment, Metastatic Malignant Neoplasm in the Brain
Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients With Brain Metastases
This randomized phase III trial compares memantine hydrochloride and whole-brain radiotherapy with or without hippocampal avoidance in reducing neurocognitive decline in patients with cancer that has spread from the primary site…
- Conditions
- Cognitive Impairment, Metastatic Malignant Neoplasm in the Brain, Solid Neoplasm
- Trial name
- NCT02360215
- Testing
- Whole brain radiation therapy with hippocampal avoidance, Memantine, Whole brain radiation therapy
- Where
- 220 sites in United States, Canada
- Volunteers
- 518 people
- Sponsor
- NRG Oncology
Cognitive/Functional Effects, Metastatic Cancer
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
RATIONALE: Radiation therapy uses high energy x-rays to kill tumor cells. PURPOSE: This phase II trial is studying how well avoiding the hippocampus during whole-brain radiation therapy works in treating patients with brain…
- Conditions
- Cognitive/Functional Effects, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT01227954
- Testing
- intensity-modulated radiation therapy
- Where
- 63 sites in United States, Canada
- Volunteers
- 113 people
- Sponsor
- Radiation Therapy Oncology Group